INTRODUCTION
============

Pediatric low-grade gliomas are heterogeneous and include the entities such as pilocytic astrocytoma (PA), pilomyxoid astrocytoma, and diffuse fibrillary astrocytoma. Pilocytic astrocytomas are the most prevalent, accounting for 23.5% of childhood central nervous system tumors ([@R1]). Survivals are also variable, with the 5-year survival in PAs (World Health Organization \[WHO\] grade I) reported as high as 100% when the tumor can be completely resected compared with 45% in diffuse fibrillary astrocytoma (WHO grade II) ([@R2]). Pilocytic astrocytomas are slow growing and, although many are cured by gross total resection, approximately 20% are located at unresectable sites such as the optic tract and hypothalamus and therefore tend to recur ([@R1]).

Jones et al ([@R3]) described a novel fusion oncogene comprising *KIAA1549* and *BRAF* formed through the tandem duplication at the 7q34 locus in 66% of PAs but not in high-grade gliomas. This study found 3 fusion variants, which in total account for 96% of fusion variants in the literature ([@R3]--[@R6]). The most common fusion is between exon 16 of *KIAA1549* and exon 9 of *BRAF* (63%), with less common fusion variants including exon 15-exon 9 (23%) and exon 16-exon 11 (10%) ([@R3]--[@R6]). All fusions were found to have constitutive BRAF kinase activity and transforming ability in NIH5T3 cell lines ([@R3]). The constitutive kinase activity of KIAA1549-BRAF fusion oncoprotein is caused by the loss of the BRAF autoregulatory N-terminal domain while the C-terminal kinase domain is retained ([@R7]). Forshew et al ([@R8]) found *KIAA1549-BRAF* fusion variants in both diffuse fibrillary astrocytomas and pilomyxoid astrocytomas, albeit at lower frequency than that observed in PAs. The evidence for the specificity of *BRAF* rearrangements for PAs is divided, with several reports suggesting no cases of BRAF fusion proteins in a spectrum of low-grade gliomas, including ganglioglioma, desmoplastic infantile low-grade glioma, dysembryoplastic neuroepithelial tumor, pilomyxoid astrocytoma, and pleomorphic xanthoastrocytoma ([@R5], [@R9]--[@R12]), and yet in other cohorts, *BRAF* rearrangements have been reported in up to 15% of nonpilocytic low-grade gliomas ([@R13]--[@R15]).

Subsequent research has unveiled several other rare novel *BRAF* fusion genes and fusion genes involving *RAF1*, another RAF kinase involved in the mitogen-activated protein kinase (MAPK) pathway, accounting for approximately 4% of all reported gene fusions in PAs ([@R5], [@R6], [@R16]--[@R19]). For example, Cin et al ([@R6]) identified the known *KIAA1549-BRAF* fusions, the *SRGAP3-RAF1* fusion, and described a novel fusion between *FAM131B* and *BRAF* in a large cohort of PAs. Constitutive activation of BRAF in PAs can also occur through a point mutation in the *BRAF* kinase domain, *c.1799T\>A* p.Val600Glu (commonly referred to as V600E). This mutation is common in a wide variety of tumor types and has been reported in 6.2% of PAs ([@R15]).

The *KIAA1549-BRAF* fusion is a useful putative diagnostic marker particularly for PAs, which can show the neuropathologic features of necrosis and microvascular proliferation, which are also seen in high-grade gliomas ([@R1]). It was originally reported that there was no significant difference in survival at follow-up of fusion-positive versus fusion-negative PAs ([@R3]). By exploring the significance of the fusion in a clinically relevant cohort of subtotally resected tumors outside the cerebellum, Hawkins et al ([@R20]) subsequently found that the *KIAA1549-BRAF* fusion was an independent prognostic marker for significantly improved 5-year progression-free survival for PAs, as well as grade II diffuse and pilomyxoid astrocytomas. Younger patients with infratentorial posterior fossa PAs tend to display a high frequency of the *KIAA1549-BRAF* fusion ([@R10], [@R21]). Supratentorial tumors are less frequently fusion positive but have an increased frequency of the oncogenic BRAFV600E mutation ([@R7], [@R13], [@R22]). Currently, there are clinical trials for BRAF and MAPK inhibitors for pediatric gliomas ([@R23]).

The differential neuropathologic diagnosis for PAs includes pediatric high-grade gliomas, most of which have recently been associated with histone mutations (H3.3 K27M) ([@R24]). Thus, in addition to *BRAF* screening, analysis of H3.3 K27M status is a useful additional biomarker that should be negative in a histologically confirmed PA case ([@R24]).

Here, we tested for the *BRAF* fusion, BRAFV600E, and histone H3K27me3 biomarkers and attempted to correlate them with the clinical outcome in a cohort of pediatric PA patients.

MATERIALS AND METHODS
=====================

Clinical Cohort
---------------

The cases included 32 patients. The male:female ratio was 10:22, and the age range was 6 months to 17 years 4 months. There were 13 PAs in the cerebellum, 10 in the hypothalamus, 1 in the brainstem, 1 in the third ventricle, 1 in the fourth ventricle, 3 in the optic pathway, and 3 tumor locations were unknown (Table [1](#T1){ref-type="table"}). Adjuvant therapies included radiotherapy (50--54 Gy in 28--30 fractions), chemotherapy (carboplatin, etoposide, vinblastine, vincristine), and proton therapy. In terms of completeness of resection, 9 (38%) of 24 had a documented partial resection, and 15 (62%) had a documented complete resection.

###### 

Patient Clinical Data
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BRAF Fusion Reverse Transcription Polymerase Chain Reaction
-----------------------------------------------------------

RNA was extracted from macrodissected formalin-fixed paraffin-embedded (FFPE) sections using the RNeasy FFPE kit following the manufacturer's instructions (Qiagen, Manchester, UK). RNA was reverse transcribed to cDNA using the High-Capacity cDNA RT kit following the manufacturer's instructions (Applied Biosystems, Warrington, UK). Real- time PCR was performed using 2.5 μL of cDNA, primers, and TaqMan probes specific for the *KIAA1549* and *BRAF* fusion as per Tian et al ([@R4]). Glyceraldehyde phosphate dehydrogenase was used as a control (Assays-on-Demand Gene Expression Product Hs02758991) using the TaqMan Gene Expression Mastermix and the ABI 7500 Real-time PCR instrument (all from Applied Biosystems). Primers were used at 0.9 mmol/L final concentration and probes at 0.25 mmol/L final concentration. Polymerase chain reaction conditions were 2 minutes at 50°C, 10 minutes at 95°C, and then 50 cycles of 15 seconds at 95°C and 1 minute at 60°C.

Fluorescence In Situ Hybridization for *KIAA1549-BRAF* Fusion
-------------------------------------------------------------

The *BRAF* fusion reverse transcription polymerase chain reaction (RT-PCR) results were confirmed by fluorescence in situ hybridization (FISH) analysis in a subset of cases. Formalin-fixed paraffin-embedded sections were deparaffinized and pretreated using the SPOT-Light Tissue Pretreatment kit (Invitrogen, Warrington, UK), and FISH was undertaken using Kreatech Poseidon *BRAF-KIAA1549* (7q34) Triple-Colour Fusion probe with DAPI counterstain. At least 200 interphase nuclei were examined by 2 analysts for each sample.

Immunohistochemistry
--------------------

BRAF V600E (clone VE1) and anti-histone H3.3 K27M rabbit polyclonal antibody (dilution 1:500, CAT No. ABE419; Merck Millipore, Billerica, MA) immunohistochemistry were performed as previously described ([@R24], [@R25]).

Statistical Analysis
--------------------

The χ^2^ test was used to determine the association of the 15-9 fusion with tumor location. Kaplan-Meier survival analyses were used to assess age, sex, tumor location, 16-9 fusion, and 15-9 fusion associations with overall survival; p \< 0.05 was considered significant.

RESULTS
=======

A cohort composed of 32 PA patients was successfully tested using the *BRAF* fusion RT-PCR assay, BRAF V600E, and histone H3.3 K27M. In the cohort of 32 patients, the *BRAF* fusion was identified in 24 cases (75%). All cases were negative for the H3.3 K27M, as expected. All tumors were also negative for BRAF V600E (Table [1](#T1){ref-type="table"}). Of the BRAF fusion-positive cases, 10 (42%) had only the 16-9 fusion and 8 (33%) had only the 15-9 fusion. Five (21%) of the 24 patients had multiple fusions, 4 (17%) showed both the 16-9 fusion and a low-level 16-11 fusion, and 1 (4%) showed both the 16-9 fusion and a 15-9 fusion (Table [2](#T2){ref-type="table"}). One patient (4%) exclusively had the 16-11 fusion. Multiple biopsy samples across different time points were available for 8 patients. In 7 (87%) of these 8 patients, the results from the multiple biopsies were identical. In 1 (13%) of the 8 patients, both biopsies sampled had the 16-9 fusion but the 16-11 fusion was detected at a very low level in only one of the biopsies.
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Clinical follow-up showed that 7 (22%) of the 32 patients were deceased, and 25 (78%) were alive between 2 and 14 years after initial biopsy. The deceased group had a male: female ratio of 3:4, with an age at diagnosis range of 2 years to 13 years 6 months.

In 2 (29%) of the 7 deceased patients, the original tumor site was not noted. In the remaining 5 (71%) of this group, the tumors originated in the hypothalamus/third ventricle or optic pathway. The site of origin in the patients who were alive was recorded in 24 cases (96%). Of these, 13 (55%) were in the cerebellum, 8 (33%) were in the hypothalamus, and 1 each (4%) was in the optic pathway, brainstem, or fourth ventricle.

Of the deceased group, 1 (14%) had a complete resection and, of the remaining 6 patients (86%), the extent of surgical resection was unknown. Of the alive group, the extent of surgical resection was recorded for 23 (92%) out of 25 patients. Of these, 8 (35%) had partial resection and 15 (65%) had complete resection. As expected, tumor location and complete or partial resection were significantly related in the cohort (p \< 0.001).

Of the deceased group, 2 patients (28%) had recorded adjuvant therapy: 1 received chemotherapy alone and 1 received chemotherapy and radiotherapy. Of the alive group, 22 patients (88%) had recorded adjuvant therapy: 2 received chemotherapy and radiotherapy, 2 received radiotherapy, 1 received chemotherapy alone, 1 received chemotherapy and proton therapy, and 16 (72%) of these patients received no therapy.

The RT-PCR fusion test was positive for 5 (71%) out of 7 of the deceased group. Within this group, the type of fusion present included 2 out of 5 with 16-9 fusion, 2 out of 5 with 16-9 and 16-11 fusions, and 1 with 15-9 fusion. Of the alive group, 19 (76%) cases had a positive result for the RT-PCR and, of these, 8 (42%) had the 16-9 fusion, 7 (37%) had the 15-9 fusion, 1 (5%) had only the 16-11 fusion, and 1 (5%) was positive for both the 16-9 and the 15-9 fusions. In addition, 3 (16%) showed 16-9 fusions also with low levels of 16-11 fusions also (Table [1](#T1){ref-type="table"}).

In the 5 deceased patients, 2 (40%) had multiple fusions, whereas 4 (21%) out of 19 alive patients had multiple fusions. The small numbers of patients in this cohort precluded determining relationships of the presence of multiple fusions with clinical features and survival.

Interestingly, the 15-9 fusion was significantly associated with tumor location in the midline outside of the cerebellum (p = 0.014) (Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). Tumors located in the cerebellum were negatively associated with fusion 15-9 (p = 0.008). Tumors in the cerebellum were not significantly associated with fusion 16-9 (p = 0.080). Age (p = 0.300), sex (p = 0.261), tumor location (p = 0.177), 16-9 fusion (p = 0.208), and 15-9 fusion (p = 0.208) were not significantly associated with overall survival.
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DISCUSSION
==========

In this study of 32 PA patients, the *KIAA1549-BRAF* fusion detection rate was (24 of 32) 75% overall. This is comparable to that in the literature, with previous studies showing that 60% to 80% of PAs harbor *BRAF* fusions ([@R10], [@R20]). The BRAF V600E mutation and H3K27me3 histone methylation were not detected in the cohort.

The neuropathologic distinction of PA from malignant glioma can be challenging because biopsies of PAs tend to be small and show features such as necrosis and microvascular proliferation that are also seen in high-grade gliomas ([@R1]). Distinguishing these entities is key for appropriate treatment and accurate prognostic information for pediatric glioma patients. The *KIAA1549-BRAF* fusion is increasingly used as a diagnostic marker to aid neuropathologic diagnosis in low-grade gliomas because of its high frequency in these tumors, particularly PAs, and its absence in high-grade tumors such as anaplastic astrocytoma (WHO grade III) and glioblastoma (WHO grade IV) ([@R15]).

In our cohort, the *KIAA1459-BRAF* 16-9 fusion was the most common, accounting for 42%; the 15-9 fusion accounted for 33% and the 16-11 fusion only accounted for 4% ([@R3]--[@R6]). Twenty-one percent of our cohort had multiple fusions, with 17% showing both the 16-9 fusion and a low-level 16-11 fusion and 4% showing both the 16-9 fusion and a 15-9 fusion. Similarly, Tian et al ([@R4]) also described patients expressing more than 1 fusion variant, that is, 9% of their cohort expressed both 16-9 and 15-9 fusions, and 3% expressed both 16-9 and 16-11 fusions. The primers used in our study were identical to those used by Tian et al ([@R4]), so this could be a genuine finding or a technical artifact of the assay. Taha et al ([@R26]) reported 3 PA patients with fusions of both 16-9 and 15-9 using a different RT-PCR assay. The presence of multiple fusion transcripts may be caused by the production of several different RNA transcripts from alternative splicing or could reflect different subpopulations of the tumor, each expressing a different fusion isoform. In our cohort, it is unclear whether multiple fusions may predict a worse clinical outcome because of the small numbers with multiple fusions.

In our cohort, the *KIAA1549-BRAF* 15-9 fusion was significantly associated with tumor location in the midline (p = 0.014) and PAs located within the cerebellum were negatively associated with fusion 15-9 (p = 0.008). There is some evidence of tumors in the cerebellum being associated with fusion 16-9, but this does not achieve significance (p = 0.080). Tumors located in the hypothalamus are traditionally difficult to resect; indeed, complete resection has been reported in 94% of cerebellar PAs compared with only 3.2% of hypothalamic and chiasmatic tumors, with an overall tumor recurrence rate of 19% ([@R27], [@R28]). Our findings of an association of fusion with tumor location were not seen in the large cohort of PAs described by Jones et al; however, that study had only 2 out of 96 PAs that arose in the hypothalamus. In addition, in contrast to other studies, the cohort by Jones et al ([@R3]) did not show multiple fusions within a single tumor, raising the possibility that this finding could be an artifact of PCR.

Other studies have shown an association between location and *BRAF* alterations, but the present study is the first to demonstrate an association between *BRAF* fusion subtype and location. The *KIAA1549-BRAF* fusions are more common in posterior fossa PAs ([@R10], [@R21]), whereas supratentorial PAs are less frequently fusion positive but have an increased frequency of the oncogenic BRAFV600E mutation ([@R7], [@R13], [@R22]). More specifically, Hawkins et al ([@R20]) showed that midline supratentorial low-grade gliomas (which are usually unresectable) had a higher frequency of *KIAA1549-BRAF* fusions than lobar tumors.

In this study, age, sex, tumor location, 16-9 fusion, and 15-9 fusion were not significantly associated with overall survival; however, the small sample size, absence of some data, and small number of deaths may have precluded detection of a significant association. Two previous studies have shown that the *KIAA1549-BRAF* fusion is associated with an improved outcome in pediatric low-grade gliomas ([@R13], [@R20]), whereas 4 studies have reported no effect on outcome ([@R3], [@R13], [@R16], [@R27]).

Currently, there are several clinical trials in glioma involving agents that inhibit the MAPK pathway such as BRAF, RAF1, and MEK inhibitors ([@R15]). Although a recent phase II trial of sorafenib (multikinase inhibitor) in pediatric low-grade astrocytoma was discontinued because of rapid progression of the disease ([@R29]), combined therapy of sorafenib and an mTOR inhibitor was successful in a single patient with a spindle cell neoplasm harboring the *KIAA1549-BRAF* fusion ([@R30]). Combination therapy may therefore be a useful approach in molecularly targeting *BRAF* alterations in pediatric gliomas and should be the focus of clinical trials in this area, particularly in patients with tumors that are difficult to resect.

The *BRAF* fusions are a useful diagnostic biomarker and a potential prognostic biomarker in pediatric low-grade glioma. In the future, the identification of *BRAF* fusions may also be important for patient treatment as more targeted molecular therapies become available. It is therefore important that a diagnostic test for these fusions is readily available in a routine diagnostic setting. The *KIAA1549-BRAF* RT-PCR assay used here is very straightforward to interpret, quick to perform, amenable to FFPE tissue (some samples tested were cases more than 20 years old), and also gives additional information as to the type of fusion variant identified. However, because the RT-PCR assay detects only the 3 most common fusion variants, there could be other fusion variants present that are not detected by the assay such as *KIAA1549-BRAF* fusions involving different exons and fusions between *RAF* genes and a different gene; rare *FAM131B-BRAF*, *SRGAP3-RAF1*, *FXR1-BRAF*, *BRAF-MACF* and *QK1-RAF1* fusions have also been described ([@R6], [@R15]). Together, these rare variants not detected by the RT-PCR assay account for approximately 4% of all reported fusion variants.

In terms of reproducibility of the RT-PCR assay, in 7 (87%) of 8 of the patients with multiple biopsies, the results were identical, whereas in 1 (13%) of the 8 cases, the 16--11 fusion was detected at a very low level. The reason for this discrepancy is unclear, but it could possibly be caused by the very low expression of the 16-11 fusion in the relatively small tumor samples ([@R4]) or heterogeneity between the tumor samples. In terms of technical failure rate, in our initial validation of the RT-PCR assay, 5 patients were excluded because of low RNA concentration extracted from very small biopsy samples.

The RT-PCR is increasingly being implemented over or alongside FISH in a diagnostic setting. This is because FISH results are often very difficult to interpret because the *KIAA1549* and *BRAF* genes lie in close proximity on chromosome 7q34, and it is difficult to distinguish a fusion signal from a normal signal ([@R4]). Moreover, analysis may also be complicated by amplification of the 7q34 region in some tumors without gene fusion ([@R10]). In addition, identification of the type of fusion present may give further prognostic information in PAs, so an assay that can identify the fusion variant such as RT-PCR may be useful to implement in a diagnostic setting. Fluorescence in situ hybridization may be a useful adjunct for cases where a fusion variant has not been identified by RT-PCR or where RNA extraction is unsuccessful.

In conclusion, we have identified *KIAA1549-BRAF* fusions in 75% of patients with PA using an RT-PCR assay from FFPE tissue. In our small cohort, the *KIAA1549-BRAF* 15-9 fusion was significantly associated with PAs located outside of the cerebellum in the midline. This is the first study to demonstrate an association between *BRAF* fusion subtype and tumor location. Tumors of the midline are traditionally difficult to resect and are prone to recurrence, so further research is required to examine this observation in more detail.
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